OncoMatch/Clinical Trials/NCT06574347
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Is NCT06574347 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Vebreltinib and Osimertinib for non-small-cell lung cancer.
Treatment: Vebreltinib · Osimertinib · PLB1004 — Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
EGFRm-positive (exon 19 deletion or L858R)
Required: EGFR L858R
EGFRm-positive (exon 19 deletion or L858R)
Required: MET overexpression (IHC 3+)
MET overexpression (IHC 3+)
Required: ALK mutation
There are mutations of ALK
Required: ROS1 mutation
There are mutations of ... ROS1
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06574347 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR L858R is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify